Lung Cancer, Non-Small Cell Clinical Trial
Official title:
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] ≥ 50%), previously untreated, unresectable, locally advanced or metastatic NSCLC. Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
| Completed |
NCT03836469 -
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
|
||
| Completed |
NCT01772225 -
NSCLC Burden of Illness Study
|
N/A | |
| Completed |
NCT01362296 -
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01460472 -
Immunotherapy With Racotumomab in Advanced Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03803137 -
Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection
|
N/A | |
| Completed |
NCT00528281 -
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
|
Phase 1 | |
| Not yet recruiting |
NCT04592666 -
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00480025 -
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05784142 -
Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)
|
Phase 2 | |
| Active, not recruiting |
NCT04475939 -
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
|
Phase 3 | |
| Withdrawn |
NCT01938456 -
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT04986670 -
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
|
N/A | |
| Completed |
NCT00367679 -
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00073008 -
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04581824 -
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT00619424 -
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04940936 -
Shared Decision Making on Radiation Dose for Lung Malignancies
|
N/A | |
| Recruiting |
NCT02824952 -
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
|
Phase 2 |